Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$27,000.00

Advancing multiple myeloma treatment: Lipid nanoparticle-based chimeric antigen receptor (CAR)-natural killer (NK) therapy optimization

FY 2024-25

Summary
Chimeric Antigen Receptor (CAR) therapy is a cancer treatment in which a patient's immune cells are modified with a CAR gene, a receptor that equips them to better destroy cancer cells. Traditionally, viruses are used to deliver the gene into patients' T immune cells. However, T cell therapy can cause toxic side effects, and using viruses may pose safety risks by triggering immune reactions. Additionally, CAR-T production is expensive and lengthy, which may delay timely treatment. Alternatively, natural killer (NK) immune cells offer the same powerful cancer-fighting ability while addressing CAR-T therapy risks. Unlike T cells, CAR-NK cells do not require a genetic match with each patient, meaning they can be manufactured from healthy donors and stored. This allows an off-the-shelf therapy that is faster, more cost-effective and accessible than CAR T-cell therapy.This project focuses on improving CAR-NK therapies for multiple myeloma (MM), the second most common blood cancer. Unlike traditional methods, we use lipid nanoparticles (LNPs) as a safer, more controlled way to deliver the CAR gene to NK cells. The CAR we will develop targets BCMA, a protein highly expressed on MM cells, making it an ideal therapeutic target. We will then introduce the anti-BCMA LNPs into NK cells from both patients and healthy donors. The modified CAR-NK cells will be tested for their ability to kill MM cancer cells in laboratory experiments, mouse models, and ultimately in clinical trials. By advancing CAR-NK therapies, this research aims to create safer, more effective, and readily available treatments for MM. This project will eventually establish an NK cell platform, swapping different CARs to target a wide range of cancers, paving the way for transformative cancer treatments.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
529628
Name
Hamie Angela
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Advancing multiple myeloma treatment: Lipid nanoparticle-based chimeric antigen receptor (CAR)-natural killer (NK) therapy optimization
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adoptive Cell Therapy; Cancer Immunotherapy; Chimeric Antigen Receptor (Car) Immunotherapy; Gene Editing; Lipid Nanoparticles (Lnps); Mrna Therapeutics; Multiple Myeloma; Natural Killer (Nk) Cells; Non-Viral Delivery Systems; Off-The-Shelf Treatments
Abstract
Chimeric Antigen Receptor (CAR) therapy is a cancer treatment in which a patient's immune cells are modified with a CAR gene, a receptor that equips them to better destroy cancer cells. Traditionally, viruses are used to deliver the gene into patients' T immune cells. However, T cell therapy can cause toxic side effects, and using viruses may pose safety risks by triggering immune reactions. Additionally, CAR-T production is expensive and lengthy, which may delay timely treatment. Alternatively, natural killer (NK) immune cells offer the same powerful cancer-fighting ability while addressing CAR-T therapy risks. Unlike T cells, CAR-NK cells do not require a genetic match with each patient, meaning they can be manufactured from healthy donors and stored. This allows an off-the-shelf therapy that is faster, more cost-effective and accessible than CAR T-cell therapy.This project focuses on improving CAR-NK therapies for multiple myeloma (MM), the second most common blood cancer. Unlike traditional methods, we use lipid nanoparticles (LNPs) as a safer, more controlled way to deliver the CAR gene to NK cells. The CAR we will develop targets BCMA, a protein highly expressed on MM cells, making it an ideal therapeutic target. We will then introduce the anti-BCMA LNPs into NK cells from both patients and healthy donors. The modified CAR-NK cells will be tested for their ability to kill MM cancer cells in laboratory experiments, mouse models, and ultimately in clinical trials. By advancing CAR-NK therapies, this research aims to create safer, more effective, and readily available treatments for MM. This project will eventually establish an NK cell platform, swapping different CARs to target a wide range of cancers, paving the way for transformative cancer treatments.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hamie, Angela
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~